MP Advisors
MP Advisors Market Research Reports
| Title | published | price | |
|---|---|---|---|
Japan Biosimilars- Landscape Today Outlook Tomorrow “Biosame” entry, uninterrupted supply and companies’ strong front-end footprint requirement makes it distinct - After a decade, JP Biosimilar guidelines’s first revision expected in FY2020By MP Advisors
Since 2009, 25 biosimilars of 12 originator products are approved in Japan and have yielded mixed performances and attained annual sales of ~¥32.4b ($300m). Unique biosimilars landscape with the entry of NESP “biosame” by originato ... |
06-Jan-2020 | $4500 | |
Next Decade Generic String Of Pearls Opportunities: Sustainability Assessment With Respect To Therapeutic PositioningBy MP Advisors
The rapid growth of the generic industry has come with a number of challenges, such as heavy competition, including from authorized generics and government-mandated price cuts. All contribute to diminishing prices and ever decreasing margins. In t ... |
24-Nov-2017 | $4000 | |
The Future of the U.S. Biologics and Biosimilars Treatment Market for PsoriasisBy MP Advisors
The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6bn in 2016 is projected to almost double during the forecast period to reach $12.9bn in 2021 driven by safety and efficacy improvements of the new generation bi ... |
13-Oct-2017 | $4000 | |
Japan Biosimilars – A start of Authorized Biosimilar Era? Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market! Major JP Innovator vs. Early entrant Mid size Japanese companies- TA focus approach – A Win Win Game!By MP Advisors
In 2016, encouraging uptake of Lantus BS in Japan confirms strong foothold of the marketer, product mix targeted to DPC hospitals (Diagnostic Procedure Combination hospitals- ~4000) and early entry of the player are critical factors to decide bios ... |
14-Aug-2017 | $4000 | |
Prostate Cancer - Newer Antiandrogens & Emerging Therapies Targeting a “Watchful Waiting” and Resistance PopulationBy MP Advisors
Xtandi – Replacing competitor from Zytiga to Casodex (Bicalutamide) for a bigger pie in Prostate cancer & Finding its niche in crowded BC market Xtandi + Zytiga vs. ARN-509 + Zytiga - Who will win the ... |
01-Feb-2017 | $4500 | |
Pain Management- New Discoveries And Treatment Options In Abuse Deterrent Era • Opioids - Novel Abuse deterrent Formulation Technologies & Pipeline drugs • Emerging Novel Technologies, Mechanisms and late stage pipeline drugs in the Management of PainBy MP Advisors
Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing Opioids for Chr ... |
01-Sep-2016 | $3500 | |
India Pharma Outlook 2016: Milestones to Watch – Growth from Exports and Domestic Getting Better, Implementation of Policies under “Make-in-India”, Overture of A New MinistryBy MP Advisors
2016 will be a crucial for drug makers and consumers. During Make-in-India' week in Mumbai, Govt. highlighted many amendments or introduction of new policies with an aim to make India as a major hub for end to end drug discovery. To boost drug di ... |
17-Mar-2016 | $1500 | |
Large Cap Pharma US & EU Outlook 2016: Maximizing Their Strength On Fewer Therapy Class, Personalized Medicine, Novel Target And Biosimilars For Future GrowthBy MP Advisors
Major pharma companies are continue to improve the productivity by taking different approaches like focusing on selected therapy area and markets, merger and acquisition, divestment of non-core brands/segments and consolidation in animal health, v ... |
17-Mar-2016 | $2000 | |
Japan Pharma Outlook 2016 : JP Giants leaning in for becoming a Speciality Global PharmaBy MP Advisors
Sakigake designation - A Push from government to "Innovate"! "Essential drugs" exemption from Z2 rule- Balancing long listed pricing pressure! Authorized Generics, Biosimilars, and Patent Litigations - Avenues to grow in JP Generic ... |
10-Mar-2016 | $2500 | |
Japan Biosimilar- Active Players In Quest of a Specialty & Niche BS spaceBy MP Advisors
Filgrastim BS and Lantus BS Approval- Encouraging uptake and a lesson to fast track JP approval based on Ex-Japan data! Remicade biosimilar “NK” – A slow start does not pull back NK in starting PhIII for Herceptin BS in J ... |
01-Jan-2016 | $4000 | |
Rising Stars Outlook 2016 :New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH)By MP Advisors
Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge in the design of studies for NASH. Therefore, there ... |
01-Jan-2016 | $2000 | |
Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various GeographiesBy MP Advisors
Sales of Hepatitis C drugs crossed ~$10bn in 2014 proving that treatments for liver disease could become mega-blockbusters and Non-Alcoholic SteatoHepatitis (NASH) is expected to be equally lucrative. Improved diagnosis rate and change in tr ... |
01-Dec-2015 | $3500 | |
BUCCAL DRUG DELIVERY SYSTEMS: OPPORTUNITIES AND CHALLENGES IN BUCCAL, SUBLINGUAL FILMS, TABLETS & SPRAYS - Detailed analysis on Technologies and Pipeline DevelopmentBy MP Advisors
Within the oral mucosal cavity, the buccal region offers an attractive route of administration for systemic drug delivery. The mucosa has a rich blood supply and it is relatively permeable. The buccal mucosa offers several advantages for con ... |
01-Oct-2015 | $3000 | |
India Pharma Outlook 2015: Accelerating growth to the next level: Moving up the value chain beyond GenericsBy MP Advisors
Domestic sales improved in 2014, recovering from the slump in the 2013 caused by the market's reaction to the new drug pricing policy. In 2015, growth is expected to continue to be healthy, as the momentum continues and improving economic growth a ... |
02-Feb-2015 | $2000 | |
Japan Pharma Outlook 2015: 2015 -Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic InitiativesBy MP Advisors
The new pricing system adopted in Japan from April -2014 (Annexure 1) is a game changer initiative. It pains most of the companies - whether generic or innovator. The most of the companies are revalidating their domestic (and thus overseas) strate ... |
27-Jan-2015 | $2000 | |
Sri Lanka Pharma Market Outlook 2015: More beyond Importers & DistributorsBy MP Advisors
With the recent development, Sri Lanka's aim of developing a pharma industry should be to penetrate the global market since the internal market is not sufficient for any big firm to operate at optimum levels. According to a report published by Ind ... |
26-Jan-2015 | $2000 | |
Global Pharma US & EU Outlook 2015 : First -In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical CompaniesBy MP Advisors
Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in healthy Cash position- Will accelerate Next wave of targeted acquisition. In the recent years several new therapies have been approved in the ... |
26-Jan-2015 | $2000 | |
Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for SuccessBy MP Advisors
All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors. These companies have been able to select therapy/niche in ... |
26-Jan-2015 | $2000 | |
Dietary Supplements: World of Opportunities In the Indian Healthcare MarketBy MP Advisors
Increasing rate of chronic diseases has emphasized the need of Prevention over Intervention. These proactive health solutions include nutritional supplements which promise medical or health benefits and fall between the food and pharma chain – ‘Nutr ... |
21-Jan-2015 | $2000 | |
Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the DiseaseBy MP Advisors
While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important ... |
21-Jan-2015 | $3000 | |
- + 1 888 391 5441
- [email protected]
